Inocras and AimedBio have formed a strategic partnership to integrate whole genome sequencing and multi-omics analysis into antibody-drug conjugate clinical trials to support precision oncology drug development.

The agreement includes a strategic equity investment by AimedBio in Inocras alongside a joint research programme focused on biomarker discovery, patient selection and the identification of new cancer targets.

Under the collaboration, AimedBio will use Inocras’ whole genome sequencing platform and multi-omics analysis across its antibody-drug conjugate clinical programmes to support biomarker identification and improve patient stratification.

The companies said the partnership is intended to accelerate clinical development by incorporating comprehensive genomic analysis into ongoing oncology research while supporting the discovery of new therapeutic targets.

Jehee Suh, chief executive officer of Inocras, said: “This partnership reflects what we’ve believed from the start, that cancer whole genome data has a role beyond diagnosing cancer. It can directly shape how new treatments are developed and identify which patients are most likely to benefit.”

He added: “Bringing our cancer intelligence platform into active clinical trials with AimedBio is an important step toward accelerating precision oncology and drug discovery, and we’re happy to welcome them as a strategic partner.”

Nam-Gu Her, chief executive officer of AimedBio, said: “As ADC development grows more competitive, identifying which patients are most likely to respond to a given therapy becomes a decisive advantage.”

He added: “Inocras’s genomic capabilities will support biomarker research, patient stratification, and the discovery of next-generation cancer targets, further strengthening AimedBio’s precision oncology platform.”

The companies also plan to explore future commercial opportunities linking AimedBio’s precision drug screening capabilities with Inocras’ diagnostic platform, although the immediate focus of the collaboration is the application of whole genome sequencing to antibody-drug conjugate clinical development.